Role of Bispecific antibody for Multiple Myeloma; A literature Review

Abstract

Multiple myeloma (MM), as defined by a clonal plasma cell proliferation, manifests as end organ damage caused by the abnormally high monoclonal paraprotein.In this article, we have reviewed the potential benefits of Bispecific antibodies (BsAbs) in MM patients. In addition, new BsAbs developments and clinical trials for various MM targets are discussed in detail. Bispecific antibodies are the types of antibodies that have two different antigen binding sites in one molecule. There are 100 different classes of BsAb and all these can be divided into 2 main categories based on their fragments and both categories are under trials for MM.Despite some studies showing adverse effects development of these new treatments is going to greatly contribute to improve outcomes for a wide group of patients which also requires further clinical studies to be conducted with focus on demonstration of efficacy and safety profile.